Evaluation of the Effect of Er,cr:ysgg Laser Application on Peri-Implant Crevicular Fluid Receptor Activator of Nuclear Factor-Kappa B Ligand and Osteoprotegerin Levels in the Non-Surgical Treatment of Peri-Implantitis: a Randomized Clinical Trial
No Thumbnail Available
Date
2024
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Abstract
Background: This study aimed to investigate the effect of erbium, chromium doped:yttrium,scandium,gallium,garnet (Er,Cr:YSGG) laser application combined with non-surgical mechanical debridement (MD) on clinical parameters and peri-implant crevicular fluid receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin (OPG) levels in the treatment of peri-implantitis. Methods: A total of 49 patients who underwent non-surgical treatment of peri-implantitis were randomly divided into two groups. The control group (n = 26) received MD alone, while the laser group (n = 23) received MD+Er,Cr:YSGG. The clinical parameters (bleeding on probing [BoP], gingival index [GI], plaque index [PI], probing depth [PD]), marginal bone loss (MBL), and biochemical parameters (RANKL and OPG) were measured at baseline (T0) and 6 months after treatment (T1). Results: There was a statistically significant decrease in all the clinical parameters in both groups at T1 compared to T0 (p < 0.05). The BoP, PD, MBL, and RANKL reductions were significantly higher in the laser group than in the control group (p = 0.046, p = 0.014, p = 0.047, p = 0.045, respectively). The OPG levels significantly increased at T1 in the laser group (p = 0.01). The OPG/RANKL ratio increased significantly in both groups at T1, which favored the laser group (p = 0.034). Conclusions: Although both treatment methods were influential in treating peri-implantitis, the laser group (MD+Er,Cr:YSGG) yielded more favorable results by reducing clinical inflammation and improving biochemical parameters. Based on these findings, Er,Cr:YSGG laser may be a beneficial adjunctive treatment in this patient group.
Description
Altindal, Dicle/0000-0001-6127-373X; Talmac, Ahmet Cemil/0000-0002-7401-0936; Ertugrul, Abdullah Seckin/0000-0002-9973-3161; Keskin Tunc, Serap/0000-0001-5439-6598; Alpaslan, Nazli Zeynep/0000-0002-6311-385X
Keywords
Biomarkers, Clinical Trial, Lasers, Osteoprotegerin, Peri-Implantitis, Rankl
Turkish CoHE Thesis Center URL
WoS Q
Q1
Scopus Q
Q1
Source
Volume
95
Issue
10
Start Page
917
End Page
928